

# Resource Summary Report

Generated by [nidm-terms](#) on Aug 23, 2026

## B6.129S2-Cd8a<sup>tm1Mak</sup>/J

RRID:IMSR\_JAX:002665

Type: Organism

### Proper Citation

RRID:IMSR\_JAX:002665

### Organism Information

**URL:** <https://www.jax.org/strain/002665>

**Proper Citation:** RRID:IMSR\_JAX:002665

**Description:** Mus musculus with name B6.129S2-Cd8a<sup>tm1Mak</sup>/J from IMSR.

**Species:** Mus musculus

**Notes:** gene symbol note: CD8 subunit alpha; mutant strain|congenic strain: Cd8a

**Affected Gene:** CD8 subunit alpha

**Genomic Alteration:** targeted mutation 1; Tak Mak

**Catalog Number:** JAX:002665

**Database:** JAX Mice and Services

**Database Abbreviation:** JAX

**Availability:** live

**Organism Name:** B6.129S2-Cd8a<sup>tm1Mak</sup>/J

**Record Creation Time:** 20250513T053634+0000

**Record Last Update:** 20260815T050543+0000

### Ratings and Alerts

No rating or validation information has been found for B6.129S2-Cd8a<sup>tm1Mak</sup>/J.

No alerts have been found for B6.129S2-Cd8a<sup>tm1Mak</sup>/J.

---

## Data and Source Information

**Source:** [Integrated Animals](#)

**Source Database:** JAX Mice and Services

---

## Usage and Citation Metrics

We found 99 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [nidm-terms](#) .

Schmiechen ZC, et al. (2026) Treg cells promote immunotherapy-induced immune evasion by restraining CD4 T cell control of MHC-I-deficient metastatic pancreatic cancer. *Science immunology*, 11(120), eadz4302.

Ökten AB, et al. (2026) IgA is necessary and sufficient to prevent norovirus infection in mice. *Science translational medicine*, 18(855), eaeb4878.

Shimizu K, et al. (2025) Distinct TAM subset with cross-dressing capability determines the bifurcation of tumor immunity. *Cell reports*, 44(6), 115800.

Herrmann C, et al. (2025) Environmental stress drives clearance of a persistent enteric virus in mice. *Nature microbiology*, 10(8), 1975.

Sharma P, et al. (2025) Smoking-induced gut microbial dysbiosis mediates cancer progression through modulation of anti-tumor immune response. *iScience*, 28(3), 112002.

Schiele P, et al. (2025) CD8+ T cell-derived CD40L mediates noncanonical cytotoxicity in CD40-expressing cancer cells. *Science advances*, 11(21), eadr9331.

Purbey PK, et al. (2024) Opposing tumor-cell-intrinsic and -extrinsic roles of the IRF1 transcription factor in antitumor immunity. *Cell reports*, 43(6), 114289.

Xue G, et al. (2024) Clinical drug screening reveals clofazimine potentiates the efficacy while reducing the toxicity of anti-PD-1 and CTLA-4 immunotherapy. *Cancer cell*.

Mahadevan KK, et al. (2024) Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer. *Science (New York, N.Y.)*, 384(6703), eadh4567.

Ran L, et al. (2024) The transcription regulator ID3 maintains tumor-specific memory CD8+ T cells in draining lymph nodes during tumorigenesis. *Cell reports*, 43(9), 114690.

Abdelwahab T, et al. (2023) Cytotoxic CNS-associated T cells drive axon degeneration by targeting perturbed oligodendrocytes in PLP1 mutant mice. *iScience*, 26(5), 106698.

Dmello C, et al. (2023) Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade. *Nature communications*, 14(1), 1566.

Ma L, et al. (2023) Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. *Cell*, 186(15), 3148.

Golden JW, et al. (2023) Induced protection from a CCHFV-M DNA vaccine requires CD8+ T cells. *Virus research*, 334, 199173.

Ravindranathan S, et al. (2022) Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma. *Nature communications*, 13(1), 6418.

Démoulins T, et al. (2022) Induction of thymic atrophy and loss of thymic output by type-I interferons during chronic viral infection. *Virology*, 567, 77.

Haase S, et al. (2022) H3.3-G34 mutations impair DNA repair and promote cGAS/STING-mediated immune responses in pediatric high-grade glioma models. *The Journal of clinical investigation*, 132(22).

John J, et al. (2022) Divergent outcomes of anti-PD-L1 treatment coupled with host-intrinsic differences in TCR repertoire and distinct T cell activation states in responding versus non-responding tumors. *Frontiers in immunology*, 13, 992630.

Anastasaki C, et al. (2022) Human induced pluripotent stem cell engineering establishes a humanized mouse platform for pediatric low-grade glioma modeling. *Acta neuropathologica communications*, 10(1), 120.

Huang Q, et al. (2022) The primordial differentiation of tumor-specific memory CD8+ T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes. *Cell*, 185(22), 4049.